Persisting Chronic Myeloid Leukemia Stem and Progenitor Cells From Patients in Major Molecular Remission Under Imatinib Are Characterized by Low BCR/ABL Expression.
Ashu Kumari(Philipps University of Marburg), Andreas Burchert(Philipps University of Marburg), Cornelia Brendel(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Sonja Tajstra(Universitätsklinikum Gießen und Marburg), Thorsten Volkmann(National Institutes of Health)
Cited by 0
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573